In early arthritis (RA) pts there is no value in measuring for IgA-ACPA or IgA-RF, as there presence doesnt provide more than IgG-ACPA. In tREACH trial IgA-ACPA present in 23% & overlaped w/ IgG-ACPA in 94% (w/ IgM-RF in 90%). https://t.co/d8Xc4GBfEt https://t.co/qvujVx0RFf